Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Merck & Co. synthesizes novel IRAK inhibitors

Sep. 3, 2014

Novo Nordisk to discontinue R&D activities for inflammatory disorders

Sep. 2, 2014

Ablynx signs license agreement with Eddingpharm to develop ozoralizumab

Sep. 2, 2014

Pfizer Japan receives additional indication approval for Solu-Medrol

Sep. 2, 2014

Nissan Chemical prepares novel JAK inhibitors

Sep. 1, 2014

FDA approves Zorvolex for management of osteoarthritis pain

Aug. 26, 2014

Korean scientists present new anti-C5 MAbs

Aug. 22, 2014

Mount Tam Biotechnologies licenses lupus candidate from Buck Institute

Aug. 20, 2014

Ampio Pharmaceuticals reports data from multiple-injection study of Ampion

Aug. 19, 2014

Merck & Co. presents novel BTK inhibitors

Aug. 19, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.